ArticleMedical oncology (Northwood, London, England)2014
Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- Sacral chordomas: surgical management, reconstruction, and translational advances: a systematic review.Journal of spine surgery (Hong Kong) · 2026Review
- KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway.Heliyon · 2024Article
- Expression of mTOR in normal and pathological conditions.Molecular cancer · 2023Review
- Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas.Cancers · 2023Article
- Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line.Journal of personalized medicine · 2023Article
- Mayo Clinic Clival Chordoma Case Series: Impact of Endoscopic Training on Clinical Care.Cancers · 2022Article
- Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma.Frontiers in oncology · 2022Article
- Bibliometric analysis of the global research trends and hotspots in chordoma from 2000 to 2020.PloS one · 2022Article
- PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells.Frontiers in surgery · 2022Article
- AZD8055 enhances in vivo efficacy of afatinib in chordomas.The Journal of pathology · 2021Article
- Midterm prognosis and surgical implication for clival chordomas after extended transsphenoidal tumor removal and gamma knife radiosurgery.BMC neurology · 2021Article
- Synergistic drug combinations and machine learning for drug repurposing in chordoma.Scientific reports · 2020Article
- Deficiency ofOncoTargets and therapy · 2020Article
- The clinical outcomes for chordomas in the cranial base and spine: A single center experience.Medicine · 2019Article
- Defining preoperative imaging findings of sacral chordomas associated with decreased overall survival and local recurrence.Journal of spine surgery (Hong Kong) · 2019Article
- Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.Frontiers in oncology · 2019Article
- Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.Cancer science · 2019Article
- Chordoma of the Head and Neck: A Review.Head and neck pathology · 2018Review
- Clinicopathologic implications of CD8Cancer immunology, immunotherapy : CII · 2018Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacral chordoma is an aggressive, locally invasive neoplasm, and has a poor prognosis. However, the molecular basis for the clinical behavior remains unknown. The purpose of this study was to investigate the expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and mammalian target of rapamycin (mTOR) in sacral chordoma, and explore their roles in the prognosis. PTEN and mTOR were detected immunohistochemically in 40 sacral chordoma tissues and 10 adjacent normal tissues. Correlations between PTEN and mTOR expression and clinicopathological factors were analyzed. Kaplan-Meier survival curves and log-rank test were used to analyze the continuous disease-free survival time (CDFS). The expression of PTEN in sacral chordoma was significantly lower than that in adjacent normal tissues, while the levels of mTOR expression in sacral chordoma were significantly higher than that in adjacent normal tissues (P = 0.000, P = 0.030). The positive expression of mTOR appears to correlate with the negative expression of PTEN in sacral chordoma (P = 0.021). PTEN-negative expression and mTOR-positive expression were associated with tumor invasion into the surrounding muscles (P = 0.038, P = 0.014). Log-rank test showed that PTEN-negative and mTOR-positive expressions had an important impact on the patients' CDFS (P = 0.011, P = 0.015). Our results suggest that PTEN and mTOR might play an important role in the local invasiveness of sacral chordoma. PTEN and mTOR might be recognized as important prognostic predictors of recurrence and could be used as potential therapeutic targets for the treatment for sacral chordoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.